Brief: BioPorto Q3 EBIT Loss Widens To DKK 11.5 Million

BioPorto A/S

08/11/2018 07:58

Nov 8 (Reuters) - BioPorto A/S  BIOPOR.CO :
    * REG-INTERIM REPORT, THIRD QUARTER 2018, BIOPORTO GROUP
    * FDA CLEARANCE OF NGAL TEST EXPECTED BY MID-2019
    * OUTLOOK FOR 2018 MAINTAINED
    * PLANS TO INITIATE A CLINICAL STUDY WITH 150-200 ADDITIONAL PATIENTS
    * Q3 REVENUE DKK 5.4 MILLION VERSUS DKK 6.0 MILLION YEAR AGO
    * Q3 EBIT LOSS DKK 11.5 MILLION VERSUS LOSS DKK 10.7  MILLION YEAR AGO

Source text for Eikon:  ID:nGNE98h1zK 
Further company coverage:  BIOPOR.CO 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))